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Summary
The objective of this study was to investigate if cellular reac-
tivity to collagen type I exists in dogs with unilateral cranial
cruciate ligament (CrCL) rupture and if it relates to disease
progression. The patient group consisted of 10 dogs with
unilateral CrCL rupture. The control dogs consisted of three
healthy control dogs, and two healthy dogs with unilateral
sham operations of the stiﬂe joint. All dogs were assayed
repeatedly every 6 months for 12–24 months. Peripheral blood
mononuclear cells were isolated from whole blood and were
cultured with human collagen type I at concentrations of 5,
20 and 40 lg/ml for 6 and 7 days. Lymphocyte reactivity to
collagen type I occurred not only in dogs with CrCL rupture,
but also in sham-operated dogs and healthy dogs. Five of the
eight assays (63%) performed at the time of operation or at the
time of diagnosis of CrCL rupture had a stimulation index (SI)
‡3.0. This was not signiﬁcantly diﬀerent compared to healthy
control dogs, not to the sham-operated control dogs. The
CrCL rupture was assessed intraoperatively in six cases. Three
cases had partial rupture and three had complete rupture. Only
one dog with partial rupture, and two dogs with complete
rupture had a positive SI. An increase in proliferation to col-
lagen type I was seen in dogs with CrCL rupture, whereas it
either remained stable or decreased in the control dogs. No
distinct pattern in lymphocyte reactivity to collagen type I
could be established from the dogs that sustained a CrCL
rupture in the contralateral stiﬂe joint, although most dogs
that did not sustain a CrCL rupture in the contralateral stiﬂe
joint remained negative during this study with exception of one
dog. Further research is required to determine whether cellular
reactivity to collagen type I may play an initiating role in
cruciate degradation.
Introduction
Rupture of the cranial cruciate ligament (CrCL) is the most
prevalent condition that aﬀects the stiﬂe joint in dogs. Partial
or complete rupture of this ligament results in instability and
inﬂammation of the stiﬂe joint, and ﬁnally in osteoarthritis
(OA). In the majority of the dogs, CrCL rupture occurs under
normal daily loading, which normally should not damage this
ligament. Despite excessive research, minimal progress has
been made in understanding the changes that leads to the
structural failure of the CrCL. Histopathological studies on
synovial tissues from dogs with CrCL rupture reveal a chronic
synovitis with inﬁltration of T lymphocytes, plasma cells and
macrophages (Tirgari, 1977; Galloway and Lester, 1995;
Lawrence et al., 1998; Hewicker-Trautwein et al., 1999), being
suggestive for a cellular immune reaction. A recent histopath-
ological study discovered a signiﬁcant quantity of dendritic-
like cells in the synovial tissue of dogs with natural occurring
CrCL rupture (Lemburg et al., 2004). Dendritic cells are highly
potent antigen presenting cells (APC) that take up, process and
present antigen to naı¨ve T cells. The antigen(s) presented by
the dendritic cells in the synovium of stiﬂe joints with CrCL
rupture is (are) still unknown. However, one of the major
components of joint tissue is collagen, and cellular reactivity to
collagen has been reported in collagen-induced arthritis (CIA)
in rodents and in rheumatoid arthritis (RA) in humans
(Smolen et al., 1980; Kammer and Trentham, 1984). The
cruciate ligaments, as well as the menisci, are mainly composed
of collagen type I while the articular cartilage is mostly
composed of collagen type II (Amiel et al., 1984; Morgan
et al., 1987). It is, therefore, possible that collagen type I is a
critical self-antigen in cruciate disease in dogs. An intriguing
mystery in cruciate disease in dogs is the high occurrence of
contralateral ruptures; one-third of the cruciate patients
rupture their contralateral CrCL within 8 months after the
ﬁrst CrCL rupture (Pond and Campbell, 1972; Bennett et al.,
1988; Doverspike et al., 1993; de Rooster, 2001). A possible
explanation is that activated T cells against collagen type I
enter the contralateral stiﬂe joint and generate an inﬂamma-
tory reaction that could ultimately result in degradation of the
CrCL.
Proliferation assays performed with peripheral blood
mononuclear cells (PBMC) are commonly used to investi-
gate the reactivity of PBMC against a speciﬁc antigen (Barta
and Barta, 1993). The objective of this study was to
investigate the lymphocyte reactivity to collagen type I in
dogs with CrCL rupture with a lymphocyte proliferation
assay, and to discuss its possible role in the disease
progression.
Materials and Methods
Control groups
Healthy control dogs
Three healthy experimental dogs were used as healthy control
dogs. The dogs were kept at the Faculty of Veterinary
Medicine and were housed, fed and cared for in accordance
with institutional and ethical guidelines. They were examined
before initiation of the study to exclude any musculoskeletal
abnormalities. Radiographs of the shoulder, the elbow, the
stiﬂe and hip joints showed no signs of OA. Lymphocyte
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proliferation assays to collagen type I were performed every
6 months for a total of three to four times.
Sham-operated dogs
A sham operation was performed on the left stiﬂe joint of two
healthy dogs. Both dogs were kept at the Faculty of Veterinary
Medicine andwere housed, fed and cared for in accordance with
institutional and ethical guidelines. They were examined before
the initiation of this study to exclude any musculoskeletal
abnormalities. Radiographs of the shoulder, the elbow, the stiﬂe
and hip joints showed no signs of OA. The stiﬂe joint was
approached through a lateral arthrotomy. The patella was
dislocated medially and a Gelpi retractor andWallace retractor
were used to open the stiﬂe joint to inspect the intra-articular
structures. There were no signs of OA, cruciate ligament or
meniscal damage. The joints were routinely closed using single
sutures of polyglactin 910 (Vicryl; Johnson & Johnson,
Dilbeek, Belgium). The dogs were allowed limited exercise for
6 weeks. Lymphocyte proliferation assays to collagen were
performed only after the shamoperation as the assaywas not yet
optimized at the time of operation. The assays were performed
every 6 months, starting 6 months after the sham operation.
The entire study with the healthy control dogs and the sham-
operated dogs was approved by the ethical commission of the
Faculty of Veterinary Medicine, Ghent University, Belgium.
Patient group
Ten client-owned dogs admitted to the Ghent University,
Veterinary School, Department of Diagnostic Imaging diag-
nosed with unilateral CrCL rupture were included in the
present study. The owners gave written consent to present their
dogs for re-examination every 6 months for 12–24 months.
Diagnosis of CrCL rupture was based on hind limb lameness,
palpable cranial drawer movement (with the exception of one
dog), signs of OA and positive tibial compression test on
standard mediolateral radiographs. Breed, age at time of initial
presentation, body weight and sex were recorded. Data on the
duration of lameness were available of all dogs. The aﬀected
stiﬂe joints were stabilized using an extracapsular technique
using sutures of polyglacin 910 (Vicryl). In some dogs, the
lymphocyte proliferation assays to collagen could not be
performed at the time of initiation of this study as the assay
was not yet optimized at that time-point.
Collagen
Highly puriﬁed human collagen type I (Southern Biotechno-
logy Associates Inc., Birmingham, AL, USA) was dialysed
against phosphate-buﬀered saline (PBS) solution (Gibco BRL;
Life Technologies, Merelbeke, Belgium) for 24 h at 4C. The
collagen was aliquoted and stored at )18C until use. Thawing
was performed by incubation at 4C.
Blood sampling
A volume of 20 ml blood was aseptically collected from the
jugular vein into 50 ml syringes containing 20 ml PBS (Gibco)
supplemented with 1% penicillin (100 IU/ml) (Gibco), strep-
tomycin (100 lg/ml) (Gibco) and heparin 150 IU/ml (Hepa-
rine Rorer, Aventis, Belgium) for the isolation of PBMC.
In addition to the 20 ml of blood for lymphocyte isolation,
4 ml of blood was aseptically collected for the isolation of the
autologous serum.
Isolation of PBMC
The method for isolating canine PBMC was previously
described (de Bruin et al., 2005 ). Brieﬂy, diluted blood was
supplemented with 10% (v/v) of a carbonyl iron/arabic gum
mixture that was prepared as follows: a 10% (w/v) carbonyl
iron suspension (Sigma, Bornem, Belgium) in 10 ml PBS
supplemented with 1% penicillin (100 IU/mL) was washed
four times with this solution (centrifugation for 10 min at
550 g and RT). Meanwhile, a 10% (w/v) arabic gum suspen-
sion (Sigma) in 10 ml PBS with 1% penicillin was prepared.
Both were sterilized for a period of 15 min at 121C. After
cooling, equal amounts of the two suspensions were mixed.
The supplemented blood was incubated for 1 h at 38C in a
5% CO2 atmosphere, during which it was gently shaken every
10 min. After incubation, the 22 ml of blood was carefully
layered onto 15 ml dense medium in a 50 ml falcon tube
[Thedensemedium(density1.079 g/cm3;osmolality256 mOsm)
is prepared by dissolving 7.1 g of FicollTM PM400 (Amersham
Bioscience, Roosendaal, The Netherlands) and 9 g of sodium
diatrizoate (Sigma) in 100 ml aqua dest.] and density gradient
centrifugation [900 g for 30 min at room temperature (RT)]
was performed. After centrifugation, cells from the interface
were aspirated by pipette and diluted with an equal amount of
Alsevers solution (Gibco) (supplemented with 1% heat-
inactivated homologous serum (HS) (Gibco), 1% penicillin
(100 IU/mL) (Gibco) and streptomycin [100 lg/ml) (Gibco)]
and pelleted by centrifugation (550 g for 15 min at RT). When
necessary, the remaining erythrocytes were lysed with ammo-
nium chloride [0.8% (w/v)] for 10 min and the PBMC were
again diluted with an equal amount of Alsevers solution and
pelleted by centrifugation (550 g for 10 min at RT). The
PBMC were washed twice in incomplete RPMI [RPMI-1640
(Sigma) supplemented with 1% HS, penicillin (100 IU/ml) and
streptomycin (100 lg/ml)] by centrifugation (400 g for 10 min
at RT) and resuspension to remove platelets and to avoid
clotting. The PBMC were adjusted to 3 · 106 cells/ml in
leucocyte medium [RPMI-1640 supplemented with 3% auto-
logous serum, 2 mm l-glutamine (Gibco), 1 mm sodium
pyruvate (Gibco), 1% non-essential aminoacids (Gibco), 1%
penicillin (100 IU/ml), 1% streptomycin (100 lg/ml) and
50 lm 2-mercaptoethanol (2-ME) (Gibco)].
PBMC proliferation assays with collagen
Cultures were established in 96-well ﬂat-bottomed microtitre
plates (Cell star, Greiner bio-one, Wemmel, Belgium). One
hundred microlitres of cell suspensions were cultured in the
presence of 100 ll of the three collagen solutions at ﬁnal
concentrations of 5, 20 and 40 lg/ml in leucocyte medium and
in medium without collagen (unstimulated control) for 6 and
7 days at 38C in a humidiﬁed atmosphere of 5% CO2.
Eighteen hours before harvesting, cultures were pulsed with
[3H]-thymidine (1 lCi/well; Amersham ICN, Bucks, UK).
Harvesting occurred onto glass ﬁbre ﬁlters (Filter Mat; Wallac,
Turku, Finland) with an automatic Combi Cell harvester
(Skatron Instruments, model 11025, Lier, Norway). The
radioactivity incorporated into the DNA was measured using
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a b-scintillation counter (Perkin Elmer, Brussels, Belgium).
Stimulation was performed in duplicates or triplicates,
depending on the amount of PBMC isolated. Positive control
cultures consisted of PBMC with the mitogen concanavalin A
(ConA) (10 lg/ml) (Sigma) and were cultured for 24 h after
which they were pulsed with [3H]-thymidine for another 18 h.
Calculation of the stimulation index
Signiﬁcance of the lymphocyte proliferation was expressed by
using the stimulation index (SI), which is calculated as follows:
SI ¼ DCPMs
DCPMns
;
where DCPMs is the mean counts per minute of collagen-
containing cultures and DCPMns is the mean counts per
minute of collagen-free cultures.
Lymphocyte proliferation was regarded as signiﬁcant if the
SI ‡ 3.0.
Statistics
All data were analysed using the statistical software package
Statistix 4.1 (Tallahassee, FL, USA). The Mann–Whitney
rank sum tests were used to compare data, such as age, body
weight and duration of the lameness between dogs with partial
and complete CrCL rupture.
As the various data sets were not normally distributed,
results were expressed as medians (range). The Mann–Whitney
rank sum tests were used to compare the SI values between the
diﬀerent groups. Because of the small sample sizes in the
diﬀerent groups, the Fishers exact probability test was used to
compare the number of dogs with positive SI in the patient
group versus the diﬀerent control dogs, and between the
control dogs themselves. Tested hypotheses were accepted if
the P-value was £0.05.
Results
Clinical parameters
The breeds included in the diﬀerent groups are summarized in
Table 1. Mean age, body weight, presence of a meniscal tear,
and duration of lameness of the diﬀerent groups are shown in
Table 2.
The healthy control group consisted of three neutered
females. The sham-operated dogs consisted of one female and
one male.
At the initiation of the study, three dogs (30%) had
complete rupture of the CrCL, of which two (66.6%) also
had concomitant medial meniscus tear. The remaining seven
dogs (70%) had partial CrCL rupture, of which three (43%)
also had a medial meniscus tear. Eight dogs (80%) ruptured
their CrCL without history of severe trauma. Eight dogs were
female, two of them were neutered. Two dogs were male, only
one was neutered. The dogs in the partial CrCL rupture group
were signiﬁcantly heavier than the dogs with complete CrCL
rupture (P = 0.02).
No clinical signs of lameness were noticed in the healthy
control group. The sham operation dogs were slightly lame for
1–2 months post-operatively. The mean duration of lameness
in the patient group was 3.3 months (range 1–12 months). The
mean duration of lameness was longer, although not signiﬁ-
cantly, in the dogs with partial rupture (mean 4.0 months)
compared with the dogs with complete rupture (mean
1.7 months) (P = 0.17).
Lymphocyte proliferation to collagen type I
Table 3 shows the results of the collagen type I-induced
lymphocyte proliferation for PBMC of dogs with cruciate
disease and of the control dogs (healthy dogs and sham-
operated dogs). In addition, the most relevant clinical data are
presented. Lymphocyte proliferation to ConA was high in a
majority of the dogs analysed but showed considerable
variation (data not shown).
Healthy control dogs
A total of nine assays were available from these dogs (Table 3).
Three of the nine assays (33.3%) had an SI ‡ 3.0. The median
SI for all these assays was 2.4 (range 0.5–4.8). The SI of these
dogs decreased in time.
Table 1. Breeds and numbers of dogs in the diﬀerent groups
Groups Breed Number of cases
CrCL patients Golden retriever 3
American Staﬀord terrier 2
Labrador retriever 1
Boxer 1
Bernese mountain dog 1
German shepherd 1
Mixed breed 1
Total 10
Healthy controls Beagle 3
Total 3
Sham-operated dogs Foxhound 2
Total 2
CrCL, cranial cruciate ligament.
Table 2. Mean distribution
(and range) of stiﬂe joints at the
initiation of the study by age, body
weight, medial meniscus tear and
duration of lameness
Groups
Number
of dogs Age (years)
Body weight
(kg)
Number of dogs
with MMT
Duration of
lameness (mth)
CrCL-R 10 4.6 (1.0–9.5) 33.4 (25–58) 5 3.3 (1–12)
cCrCL-R 3 4.5 (1.4–9.5) 25.8 (25–28) 2 1.7 (1–2)
pCrCL-R 7 4.6 (1.0–8.2) 36.7 (28–58) 3 4.0 (1.3–12)
Healthy controls 3 3.3 (2.7–3.8) 13.3 (13–14) 0 –
Sham-operated dogs 2 3.0 (2.2 + 3.5) 23.5 (18 + 29) 0 1.5 (1 + 2)
CrCL-R, cranial cruciate ligament rupture; cCrCL-R, complete CrCL-R; pCrCL-R, partial CrCL-R;
MMT, medial meniscus tear; mth, months; nk, not known.
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Sham-operated dogs
From the two sham-operated dogs, a total of six lymphocyte
proliferation assays were available. Four of the six assays
(66.7%) had an SI ‡ 3.0. This was not signiﬁcantly diﬀerent
compared with the healthy control dogs (P = 0.31). The
median SI of this group was 3.5 (range 0.7–24.2), which was
not signiﬁcantly diﬀerent compared with the healthy control
dogs (P = 0.59). One of the sham-operated dogs (sham dog 1),
only had one positive assay (of the three assays in total),
whereas the other dog remained positive (sham dog 2), twice
with relatively high SI.
Dogs with CrCL rupture
A total of eight lymphocyte proliferation assays to collagen
type I were performed with seven dogs at the time of surgery or
diagnosis of rupture (one dog was counted twice for the time of
rupture as it was assayed at the time of surgery of the initially
aﬀected stiﬂe and at diagnosis of rupture of the contralateral
stiﬂe joint). Five of these eight assays (63%) had an SI ‡ 3.0
after stimulation with collagen type I. This was not signiﬁ-
cantly diﬀerent compared with healthy control dogs
(P = 0.15), or to the sham-operated dogs (P = 1.00). The
median SI of all dogs sampled at operation time or diagnosis
of rupture was 4.5 (range 1.1–12.1), which tended to be higher
than the SI of the healthy control dogs (2.4; range 0.5–4.8),
however, this was not signiﬁcant (P = 0.14). The status of the
CrCL rupture (partial or complete) was assessed intraopera-
tively in six of the eight cases. There were three cases with
partial CrCL rupture and three cases with complete CrCL
rupture. Only one of the three cases with partial CrCL rupture
(33.3%) had an SI ‡ 3.0, whereas two of the three with
complete rupture (66.7%) had an SI ‡ 3.0 (P = 1.00). The
median SI of the cases with partial CrCL rupture was 2.5
(range 1.1–4.6) and of the cases with complete CrCL rupture
was 7.2 (range 1.1–12.1), which was not signiﬁcantly diﬀerent
(P = 0.42).
All dogs with CrCL rupture were tested repeatedly for
lymphocyte proliferation against collagen type I at diﬀerent
time intervals. An increase in SI was seen in seven of the 10
dogs (dogs 1, 2, 3, 5, 7, 8, 10). Five of the 10 dogs sustained a
CrCL rupture in the contralateral stiﬂe joint during this study.
One dog remained negative during the entire study (dog 1), one
dog (dog 5) showed a slight increase in SI until rupture, one
dog (dog 4) was positive before and at rupture of the
contralateral CrCL. The other two dogs (dogs 2 and 3) only
had a positive SI at the time of CrCL rupture of the
contralateral stiﬂe joint. The ﬁve dogs that did not sustain a
CrCL rupture in the contralateral stiﬂe joint during this study
remained negative with exception to one dog which had a
positive SI once after rupture (dog 10) that turned negative
again.
Optimal stimulating conditions with collagen
No single dose of collagen was optimal for stimulating a
lymphocyte proliferation in all dogs, although signiﬁcantly
more dogs responded with 20 lg/ml (P = 0.008). In addition,
dogs with cruciate pathology had signiﬁcantly more lympho-
cyte reactivity to 20 lg/ml than the control dogs (P = 0.011).
Among the dogs with CrCL rupture, eight dogs responded
optimally to 20 lg/ml and none to 5 and 40 lg/ml. Of the
control dogs (healthy and shams), one responded optimally to
5 lg/ml, 2–20 lg/ml and 2–40 lg/ml. Optimal response was
seen after 6 or 7 days culture.
Discussion
To the best of our knowledge, this is the ﬁrst study investi-
gating lymphocyte responsiveness to collagen in dogs with
CrCL rupture. Our results demonstrate that sensitization to
collagen type I not only occurs in dogs with cruciate disease,
but also in sham-operated dogs and healthy dogs. This
suggests that sensitivity to collagen type I in dogs is not joint
Table 3. Evaluation of lymphocyte proliferation to collagen type I in dogs with CrCL rupture, sham-operated dogs and healthy control dogs.
Most dogs with CrCL rupture were re-examined every 6 months and had lymphocyte proliferation assays performed. Not all dogs were tested at
day 0 (surgery or initiation of the study) as the assay was not yet optimized at that moment. The stimulation indexes at the time of rupture is
shown in bold
Dog Number
Clinical
diagnosis
Disease duration
(mth) at day 0 Disease course CrCL-R initial/contra stiﬂe
Stimulation index at examination times
Day 0 6 mth 12 mth 18 mth 24 mth 30 mth
Dog 1 CrCL-R 12 R-contra 12 mth Partial/partial – 1.9 1.8 2.8 – –
Dog 2 CrCL-R 3 R-contra 12 mth Partial/complete – 2.5 12.1 – – –
Dog 3 CrCL-R 1 R-contra 12 mth Complete/complete – 1.5 6.8 – – –
Dog 4 CrCL-R 2 R-contra 18 mth Partial/unknown – 4.5 UR 3.5 – –
Dog 5 CrCL-R 0.5 R-contra 12 mth Partial/unknown 1.1 2.6 3.8 – – –
Dog 6 CrCL-R 2 Stable >8 mth Complete/stable 2.6 0.9  – – –
Dog 7 CrCL-R 2 Stable >18 mth Partial/stable – – 1.2 2.5 – –
Dog 8 CrCL-R 2 Stable >18 mth Complete/stable – – 1.8 2.1 – –
Dog 9 CrCL-R 4 Stable >18 mth Partial/stable 4.6 1.4 UR UR – –
Dog 10 CrCL-R 4 Stable >30 mth Partial/stable – – 0.25 0.89 5.7 1.2
Sham dog 1 Sham 0 – – – 0.7 3.9 UR 1.3 –
Sham dog 2 Sham 0 – – – 11.2 3.1 24.2 – –
Control dog 1 Healthy 0 – – – 2.1 3.7 1.3 0.5 –
Control dog 2 Healthy 0 – – – 4.8 1.9 1.8 – –
Control dog 3 Healthy 0 – – – – 3.4 2.1 – –
CrCL, cranial cruciate ligament; CrCL-R, CrCL rupture; mth, months; R-contra, rupture of the contralateral CrCL; Died; UR, unreliable;–, not
tested at this time-point.
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disease speciﬁc. The same has been suggested in humans, as
PBMC isolated from patients with diﬀerent arthropathies, and
healthy controls, also proliferate when cultured with diﬀerent
types of collagens (Stuart et al., 1976; Smolen et al., 1980;
Golds et al., 1983; Elkayam et al., 1991; Snowden et al., 1997;
Kim et al., 1999).
An increase in proliferation to collagen type I was seen at
the time of CrCL rupture in three of the ﬁve dogs, meaning
that the number of lymphocytes with reactivity to collagen
type I ampliﬁed over time in these patients, whereas a
decrease was seen in the healthy control dogs and one of the
sham-operated dogs. This diﬀerence in proliferation between
these groups might be due to a pre-clinical CrCL rupture in
the contralateral stiﬂe joint in the cruciate disease group.
Yet, no diﬀerence in lymphocyte reactivity to collagen type I
could be found between dogs that sustained a CrCL rupture
in their contralateral stiﬂe joint and dogs that did not during
this study. An explanation might be found in recent studies
from human patients with RA studying paired PBMC and
synovial ﬂuid mononuclear cells (SFMC) samples cultured
with collagen type II. These studies demonstrated that the
T-lymphocyte responses were more frequent and vigorous in
SFMC than in PBMC (Kim et al., 1999; Park et al., 2001;
Kim and Kim, 2005) which might suggest that these
collagen-speciﬁc T-lymphocytes home to joints. We have
not investigated SFMC reactivity to collagen type I in this
study, however, it would be worthwhile to test this concept
in the future as it could result in a clearer diﬀerentiation of
the immune response in dogs that will sustain a CrCL
rupture in their contralateral stiﬂe joint and dogs that
will not.
In conclusion, our study demonstrates that lymphocyte
reactivity to collagen type I does occur in dogs with CrCL
rupture especially at the time of symptomatic rupture. How-
ever, some of the sham-operated dogs and the healthy dogs
tested positive as well. From our results it is diﬃcult to
determine whether the presence of a cellular immune response
to collagen type I plays an initiating role in cruciate degrada-
tion or whether it evolves after ligament damage. Future
studies should focus on examining reactive lymphocytes
isolated from synovial ﬂuid.
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